Search

Your search keyword '"Hooper, M. J."' showing total 133 results
Start Over Author "Hooper, M. J."
133 results on '"Hooper, M. J."'

3. Surfactant Liquid Crystals: Phase Diagrams and Phase Behavior

Author

Shin, Sung T., Kumar, Satyendra, Greenhill-Hooper, M. J., Platz, G., Thunig, C., Hoffmann, H., Sjöblom, J., Blokhus, A. M., Friberg, S., Miller, C. A., Gradzielski, M., Kramer, U., Taddei, G., Carmona-Ribeiro, A. M., Hix, S., Chachaty, C., Bredel, T., Korb, J. P., Van der Maarel§, J. R. C., Coppola, L., La Mesa, C., Ranieri, G. A., Terenzi, M., Amaral, L. Q., Itri, R., Antón, R. E., Andérez, J. M., Graciaa, A., Lachaise, J., Salager, J. L., Amorim da Costa, A. M., Jansson, Mikael, Thurmond, Robin, Brown, Michael, Khetrapal, C. L., Katre, Y. R., Solanki, S. K., Plumley, S., Kuzma, M. R., Auvray, Xavier, Rico, I., Lattes, Armand, Friberg, S. E., Wang, J. F., Sun, W. M., López, Rafael, Millán, Sonia, Fucugauchi, Luz Alicia, Fendler, Janos H., Roy Choudhury, S., Yadav, R., Maitra, A. N., Jain, P. C., Sarraf, R., Partyka, S., Keh, E., Huang, Zhi, Gu, Tiren, Varadaraj, R., Valint, P., Bock, J., Zushma, S., Brons, N., Mittal, K. L., editor, and Shah, D. O., editor

Published
1991
Full Text
View/download PDF

9. Case Study Part 2: Probabilistic Modelling of Long-term Effects of Pesticides on Individual Breeding Success in Birds and Mammals

Author

Roelofs, W., Crocker, D. R., Shore, R. F., Moore, D. R.J., Smith, G. C., Akcakaya, H. R., Bennett, R. S., Chapman, P. F., Clook, M., Crane, M., Dewhurst, I. C., Edwards, P. J., Fairbrother, A., Ferson, S., Fischer, D., Hart, A. D.M., Holmes, M., Hooper, M. J., Lavine, M., Leopold, A., Luttik, R., Mineau, P., Mortenson, S. R., Noble, D. G., OʼConnor, R. J., Sibly, R. M., Spendiff, M., Springer, T. A., Thompson, H. M., and Topping, C.

Published
2005

11. Case Study Part 1: How to Calculate Appropriate Deterministic Long-Term Toxicity to Exposure Ratios (TERs) for Birds and Mammals

Author

Shore, R. F., Crocker, D. R., Akcakaya, H. R., Bennett, R. S., Chapman, P. F., Clook, M., Crane, M., Dewhurst, I. C., Edwards, P. J., Fairbrother, A., Ferson, S., Fischer, D., Hart, A. D.M., Holmes, M., Hooper, M. J., Lavine, M., Leopold, A., Luttik, R., Mineau, P., Moore, D. R.J., Mortenson, S. R., Noble, D. G., OʼConnor, R. J., Roelofs, W., Sibly, R. M., Smith, G. C., Spendiff, M., Springer, T. A., Thompson, H. M., and Topping, C.

Published
2005

18. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

Author

Martino, S. A, Cauley, J. A. B, Barrett Connor, E. C, Powles, T. J. D, Mershon, J. E, Disch, D. E, Secrest, R. J. E, Cummings, S. R. F, Mautalen, C. A. G, Zanchetta, J. R. H, Hooper, M. J. I, K. W. J, Ng, Prince, R. L. K, Nicholson, G. L, Roberts, A. P. M, Seeman, E. N, Williamson, M. O, Boschitsch, E. P, Leb, G. Q, Body, J. J. R, Devogelaer, J. P. S, Geusens, P. T, Kaufman, J. M. u, Peretz, A. V, Adachi, J. W, Bensen, W. X, Brown, J. P. Y, Cheung, A. Z, Chik, C. Aa, Gee, S. Ab, Hanley, D. Ac, Hawker, G. A. Ad, Hodsman, A. B. Ae, Joyce, C. Af, Monchesky, T. C. Ag, Olszynski, W. P. Ah, Roe, B. Ai, Senikas, V. Aj, Seminoski, K. Ak, Wall, J. Ab, Stepan, J. Al, Hyldstrup, L. Am, Langdahl, B. An, Sorensen, T. H. Ao, Alhava, E. Ap, Kormano, M. Aq, Salmela, P. Ar, Salmi, J. As, Valimaki, M. At, Audran, M. Au, Briancon, D. Av, Delmas, P. Aw, Fardellone, P. Ax, Ribot, C. Ay, De Vernejoul, M. C. Az, Balogh, A. Ba, Julesz, J. Bb, Szuecs, J. Bc, Karsik, A. Bd, Fiore, C. Be, Genazzani, A. R. Bf, Gennari, C. Bg, Isaia, Giovanni Carlo, Melis, G. B. Bi, Nuti, R. Bg, Oriente, P. Bj, Passeri, M. Bk, Sartori, L. Bl, Corea Rotter, R. Bm, Gonzalez, S. Bn, Murillo, A. Bo, Jonker, J. J. Bp, Lips, P. Bq, Mulder, H. Br, Pols, H. A. Bs, Halse, J. I. Bt, Hoiseth, A. Bu, Jorde, R. Bv, Olford, E. S. Bw, Skag, A. Bw, Stakkestad, J. A. Bx, Wist, E. By, Badurski, J. E. Bz, Hoszowski, K. Ca, Ogonowski, J. Cc, Bose, K. Cb, Lee, K. O. Cb, Dzurik, R. Cd, Kocijancic, A. Ce, Cannata Andia, J. B. Cf, Collado, R. C. Cg, Carranza, F. H. Ch, Diez Perez, A. Cf, Escobar Jimenez, F. Ci, Minguella, J. F. Cj, Solan, X. N. Cf, Torres, M. M. Cj, Larsson, K. Ck, and Malströem, D. Cl

Subjects
Selective Estrogen Receptor Modulators, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Breast Neoplasms, Placebo, Drug Administration Schedule, law.invention, Breast cancer, Randomized controlled trial, Double-Blind Method, Estrogen Receptor Modulators, law, Internal medicine, medicine, Humans, Raloxifene, Osteoporosis, Postmenopausal, Aged, Gynecology, business.industry, Raloxifene Hydrochloride, Incidence, Patient Selection, Lasofoxifene, Middle Aged, medicine.disease, United States, Treatment Outcome, Oncology, Selective estrogen receptor modulator, Female, business, Tamoxifen, medicine.drug
Abstract

Background: The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that 4 years of raloxifene therapy decreased the incidence of invasive breast cancer among postmenopausal women with osteoporosis by 72% compared with placebo. We conducted the Continuing Outcomes Relevant to Evista (CORE) trial to examine the effect of 4 additional years of raloxifene therapy on the incidence of invasive breast cancer in women in MORE who agreed to continue in CORE. Methods: Women who had been randomly assigned to receive raloxifene (either 60 or 120 mg/day) in MORE were assigned to receive raloxifene (60 mg/day) in CORE (n = 3510), and women who had been assigned to receive placebo in MORE continued on placebo in CORE (n = 1703). Breast cancer incidence was analyzed by a log-rank test, and a Cox proportional hazards model was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: During the CORE trial, the 4-year incidences of invasive breast cancer and estrogen receptor (ER)-positive invasive breast cancer were reduced by 59% (HR = 0.41; 95% CI = 0.24 to 0.71) and 66% (HR = 0.34; 95% CI = 0.18 to 0.66), respectively, in the raloxifene group compared with the placebo group. There was no difference between the two groups in incidence of ER-negative invasive breast cancer during CORE (P = .86). Over the 8 years of both trials, the incidences of invasive breast cancer and ER-positive invasive breast cancer were reduced by 66% (HR = 0.34; 95 % CI = 0.22 to 0.50) and 76% (HR = 0.24; 95% CI = 0.15 to 0.40), respectively, in the raloxifene group compared with the placebo group. During the CORE trial, the relative risk of thromboembolism in the raloxifene group compared with that in the placebo group was 2.17 (95% CI = 0.83 to 5.70). This increased risk, also observed in the MORE trial, persisted over the 8 years of both trials. Conclusions: The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis. No new safety concerns related to raloxifene therapy were identified during CORE. © Oxford University Press 2004, all rights reserved.

Published
2004

20. A re-examination of fipronil toxicity in birds

Author

Kitulagodage, M., Astheimer, L. B., Buttemer, W. A., Hooper, M. J., Keats, A., Kitulagodage, M., Astheimer, L. B., Buttemer, W. A., Hooper, M. J., and Keats, A.

Published
2006

31. Reply

Author

Lewitt, M. S., primary and Hooper, M. J., additional

Published
1990
Full Text
View/download PDF

37. Anaesthesia for Thyroid Surgery

Author

Holmes, J. L., Hooper, M. J., Barraclough, B. H., White, B., and Reeve, T. S.

Abstract

The principles involved in preoperative assessment and management of the patient who is to undergo thyroidectomy are discussed.The techniques of anaesthesia that have been found most successful for thyroidectomy at The Royal North Shore Hospital of Sydney are described. The effectiveness of these techniques is indicated by reference to the complications found following review of 200 consecutive thyroidectomies.

Published
1973
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results